Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) is -26.24% lower on its value in year-to-date trading and has touched a low of $24.10 and a high of $62.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRNX stock was last observed hovering at around $29.37 in the last trading session, with the day’s gains setting it 2.96%.
Currently trading at $32.33, the stock is 5.92% and 3.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.2 million and changing 10.08% at the moment leaves the stock -22.33% off its SMA200. CRNX registered -36.77% loss for a year compared to 6-month loss of -39.17%. The firm has a 50-day simple moving average (SMA 50) of $31.216 and a 200-day simple moving average (SMA200) of $41.6237.
The stock witnessed a -2.06% gain in the last 1 month and extending the period to 3 months gives it a 22.55%, and is 13.72% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.86% over the week and 3.96% over the month.
Crinetics Pharmaceuticals Inc (CRNX) has around 437 employees, a market worth around $3.03B and $0.36M in sales. Profit margin for the company is -90928.53%. Distance from 52-week low is 34.15% and -48.30% from its 52-week high. The company has generated returns on investments over the last 12 months (-25.29%).
The EPS is expected to shrink by -21.70% this year
323.0 institutions hold shares in Crinetics Pharmaceuticals Inc (CRNX), with institutional investors hold 114.72% of the company’s shares. The shares outstanding are 93.53M, and float is at 86.67M with Short Float at 11.91%. Institutions hold 112.39% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.23 million shares valued at $279.06 million. The investor’s holdings represent 7.8857 of the CRNX Shares outstanding. As of 2024-06-30, the second largest holder is DRIEHAUS CAPITAL MANAGEMENT LLC with 6.11 million shares valued at $273.76 million to account for 7.7361 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 4.62 million shares representing 5.848 and valued at over $206.95 million, while VANGUARD GROUP INC holds 5.714 of the shares totaling 4.51 million with a market value of $202.2 million.
Crinetics Pharmaceuticals Inc (CRNX) Insider Activity
The most recent transaction is an insider sale by Betz Stephen F., the company’s Chief Scientific Officer. SEC filings show that Betz Stephen F. sold 97,483 shares of the company’s common stock on Jun 12 ’25 at a price of $32.23 per share for a total of $3.14 million. Following the sale, the insider now owns 99713.0 shares.
Still, SEC filings show that on Mar 19 ’25, Pizzuti Dana (Chief Med and Dev Officer) disposed off 2,515 shares at an average price of $34.20 for $86021.0. The insider now directly holds 72,233 shares of Crinetics Pharmaceuticals Inc (CRNX).
